Research Corporation Technologies, Inc.

Washington University

Other

Ramot University Authority for Applied Research and Industrial

Terry W Moody

Wayne D Bowen

Christy S John

Jesse Baumgold

John G McAfee

Illana Gozes

Douglas E Brenneman

Matityahu Fridkin

Mati Fridkin

Edgar Gelber

The present invention relates to combination therapy using a pharmaceutical composition comprising a polypeptide which is an antagonist of the vasoactive intestinal polypeptide (VIP) and a chemotherapeutic agent. Methods of using the pharmaceutical composition are also disclosed.

Combination therapy with VIP antagonist

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

Compounds for cancer imaging and therapy

Benzamide compounds for cancer imaging and therapy

Benzamide compounds containing a heterocyclic ring for tumor imaging and

Methods for cancer imaging and therapy using benzamine compounds

Compositions and methods of use thereof for treating small cell and nonsmall cell lung cancers in mammals are disclosed. The compositions comprise substances that inhibit the lung cancer cell growth and proliferation actions of the biological response modifier vasoactive intestinal polypeptide, such as specific thymosins or analogues, derivatives and fragments thereof, anti-vasoactive intestinal polypeptide receptor polyclonal or monoclonal antibodies, and antibodies directed against the vasoactive intestinal polypeptide molecule itself.

Compositions and methods for treating small cell and nonsmall cell lung

The present invention relates to a family of peptides encoding antagonists of the vasoactive intestinal peptide (VIP) designed to distinguish multiple receptors that mediate VIP neurotransmission, neurotrophism and cell division. The invention also relates to methods of using these peptides to antagonize VIP-associated activity and function. The invention further relates to pharmaceutical compositions dsigned to inhibit VIP-associated activity.

Superactive VIP antagonists

Growing community of inventors

Germantown, MD, United States of America

Terry W Moody